GSK Acquires RAPT Therapeutics for $2.2 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Should l Buy GSK?
Source: NASDAQ.COM
- Acquisition Agreement: GSK has entered into a definitive agreement to acquire RAPT Therapeutics for an estimated equity value of $2.2 billion, with the transaction expected to close in Q1 2026, enhancing GSK's market position in immunology.
- Pipeline Expansion: The acquisition adds RAPT's ozureprubart to GSK's pipeline, targeting IgE-mediated food allergies and potentially offering new treatment options for over 17 million patients in the U.S., indicating significant market potential.
- Funding Structure: GSK's estimated upfront investment of $1.9 billion will be funded by net cash proceeds from RAPT, which will help optimize GSK's financial structure and mitigate acquisition risks.
- Positive Market Reaction: Following the announcement, RAPT's stock surged 63.53% to $57.40, reflecting strong market confidence in the deal, while GSK's stock saw a slight pre-market increase of 0.05%, indicating investor optimism about future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GSK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall
6 Analyst Rating
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 55.990
Low
20.15
Averages
38.72
High
55.60
Current: 55.990
Low
20.15
Averages
38.72
High
55.60
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. General medicines include inhaled medicines for asthma and COPD with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. It is in phase IIb clinical development for prophylactic protection against food allergens.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UK and US Reach Drug Tariff Exemption Agreement
- Drug Tariff Agreement: The UK government has reached an agreement with the US that UK-made drugs will be tariff-free for the next three years, significantly boosting UK pharmaceutical exports, which exceed £5 billion annually.
- Cost-Effectiveness Standard Increase: The deal mandates the UK's National Institute for Health and Care Excellence (NICE) to raise its cost-effectiveness threshold by 25%, which will encourage pharmaceutical companies to adjust drug pricing competitively, impacting market supply.
- New Drug Price Increase: The National Health Service (NHS) will pay 25% higher list prices for new prescription drugs, potentially increasing the financial burden on patients while also affecting pharmaceutical companies' profit structures.
- Increased R&D Investment: The UK will raise its drug R&D spending from 0.3% to 0.6% of GDP, a strategic investment aimed at enhancing the UK's competitiveness in the global pharmaceutical industry and fostering innovation and long-term growth.
See More
GSK and Shionogi Complete ViiV Healthcare Transaction
- Transaction Completion: GSK and Shionogi have finalized the transaction for ViiV Healthcare, with Shionogi increasing its economic interest from 11.7% to 21.7%, while GSK retains a majority stake of 78.3%, ensuring its dominant position in the joint venture.
- Financial Flow: In this transaction, Shionogi acquired newly issued shares of ViiV for $2.125 billion, while Pfizer's stake was canceled, resulting in Pfizer receiving $1.875 billion in cash, indicating ongoing market confidence in ViiV's prospects.
- Special Dividend: GSK received a special dividend of $250 million from the transaction, which not only enhances its cash flow but also provides funding for future investments, further solidifying its position in the pharmaceutical industry.
- Stock Performance: At the last close, GSK shares were trading at 2,064.00 pence, up 0.05%, reflecting a positive market reaction to the transaction, which may boost investor confidence in GSK's future growth potential.
See More
Pharma Stocks Pfizer and GSK Provide Safe Investment Options Amid Market Uncertainty: Charts
Pharmaceutical Stocks in Focus: Investors are increasingly interested in pharmaceutical stocks as a stable investment option amid market uncertainty.
Market Volatility Impact: The sector is gaining attention due to its steady demand and resilient earnings, which are less affected by economic fluctuations.
See More
Stock Futures Edge Higher Amid Geopolitical Tensions and Energy Market Pressures
- Bitdeer Partnership: Bitdeer Technologies (BTDR) shares rose 3% after announcing a partnership with DCI to develop its Tydal facility in Norway into an AI data center, expected to deliver 180 MW of capacity by December 2026, enhancing its competitive position in the AI sector.
- GSK Drug Approval: GlaxoSmithKline (GSK) shares gained 2% following the approval of Exdensur by China's NMPA as an add-on treatment for severe eosinophilic asthma in patients aged 12 and older, based on Phase 3 SWIFT trials showing significant reduction in exacerbation rates, likely boosting market share.
- Rocket Lab Launch Success: Rocket Lab USA (RKLB) shares advanced 2% after completing its 85th launch, successfully deploying two satellites for the European Space Agency's Celeste navigation demonstration mission, underscoring its commitment to supporting global government space programs.
- Origin Materials Revenue Drop: Origin Materials (ORGN) shares plunged 17% after reporting weak Q4 results, with revenue falling to $3.0M from $9.2M a year ago, driven by a planned reduction in its supply chain activation program, leading to a net loss of $194.1M, reflecting significant operational challenges.
See More
GSK's Exdensur Approved in China for Severe Asthma Treatment
- Drug Approval: GSK's Exdensur (depemokimab) has been approved by China's National Medical Products Administration as an add-on maintenance treatment for severe asthma in patients aged 12 and older, marking a significant advancement in the company's respiratory portfolio.
- Clinical Trial Support: The approval is based on data from the SWIFT-1 and SWIFT-2 phase III trials, demonstrating Exdensur's efficacy in improving patient symptoms, providing a robust scientific foundation for GSK's innovations in asthma treatment.
- Market Strategy: GSK's SVP, Global Head of Respiratory, Immunology & Inflammation R&D, Kaivan Khavandi, stated that with Exdensur approved in several major markets, the company aims to transform the treatment paradigm for severe asthma, further solidifying its market leadership.
- Stock Performance: At the last close, GSK shares were trading at 2,049.00 pence, and the market's reaction to the drug approval could potentially drive the stock price higher, boosting investor confidence.
See More
Vaccines Become a Backburner Issue for Trump Administration Ahead of Midterms
- Shift in Vaccine Policy: Robert Malone, a former member of the CDC's Advisory Committee on Immunization Practices, stated that the Trump administration has relegated vaccines to a secondary issue, viewing it as a 'losing issue,' which indicates a strategic pivot ahead of the midterm elections.
- Political Decision Impact: Malone highlighted that the administration has concluded that the MAHA coalition and the constituents they represent are inconsequential for the midterms, suggesting that this assessment could significantly influence the future direction of vaccine policies as voter priorities shift.
- Vaccine Injury Compensation Request: An anti-vaccine group has petitioned HHS Secretary Robert F. Kennedy Jr. to expand the list of alleged vaccine-related injuries under the Vaccine Injury Compensation Program, a move that may spark broader societal discussions and policy reconsiderations regarding vaccine safety.
- CDC Leadership Nomination Delay: The White House has missed the deadline for nominating a new CDC director, reflecting ongoing uncertainty in vaccine policy and public health leadership, which could impact future public health decisions and vaccine promotion efforts.
See More
UK and US Reach Drug Tariff Exemption Agreement
- Drug Tariff Agreement: The UK government has reached an agreement with the US that UK-made drugs will be tariff-free for the next three years, significantly boosting UK pharmaceutical exports, which exceed £5 billion annually.
- Cost-Effectiveness Standard Increase: The deal mandates the UK's National Institute for Health and Care Excellence (NICE) to raise its cost-effectiveness threshold by 25%, which will encourage pharmaceutical companies to adjust drug pricing competitively, impacting market supply.
- New Drug Price Increase: The National Health Service (NHS) will pay 25% higher list prices for new prescription drugs, potentially increasing the financial burden on patients while also affecting pharmaceutical companies' profit structures.
- Increased R&D Investment: The UK will raise its drug R&D spending from 0.3% to 0.6% of GDP, a strategic investment aimed at enhancing the UK's competitiveness in the global pharmaceutical industry and fostering innovation and long-term growth.
See More
GSK and Shionogi Complete ViiV Healthcare Transaction
- Transaction Completion: GSK and Shionogi have finalized the transaction for ViiV Healthcare, with Shionogi increasing its economic interest from 11.7% to 21.7%, while GSK retains a majority stake of 78.3%, ensuring its dominant position in the joint venture.
- Financial Flow: In this transaction, Shionogi acquired newly issued shares of ViiV for $2.125 billion, while Pfizer's stake was canceled, resulting in Pfizer receiving $1.875 billion in cash, indicating ongoing market confidence in ViiV's prospects.
- Special Dividend: GSK received a special dividend of $250 million from the transaction, which not only enhances its cash flow but also provides funding for future investments, further solidifying its position in the pharmaceutical industry.
- Stock Performance: At the last close, GSK shares were trading at 2,064.00 pence, up 0.05%, reflecting a positive market reaction to the transaction, which may boost investor confidence in GSK's future growth potential.
See More
Pharma Stocks Pfizer and GSK Provide Safe Investment Options Amid Market Uncertainty: Charts
Pharmaceutical Stocks in Focus: Investors are increasingly interested in pharmaceutical stocks as a stable investment option amid market uncertainty.
Market Volatility Impact: The sector is gaining attention due to its steady demand and resilient earnings, which are less affected by economic fluctuations.
See More
Stock Futures Edge Higher Amid Geopolitical Tensions and Energy Market Pressures
- Bitdeer Partnership: Bitdeer Technologies (BTDR) shares rose 3% after announcing a partnership with DCI to develop its Tydal facility in Norway into an AI data center, expected to deliver 180 MW of capacity by December 2026, enhancing its competitive position in the AI sector.
- GSK Drug Approval: GlaxoSmithKline (GSK) shares gained 2% following the approval of Exdensur by China's NMPA as an add-on treatment for severe eosinophilic asthma in patients aged 12 and older, based on Phase 3 SWIFT trials showing significant reduction in exacerbation rates, likely boosting market share.
- Rocket Lab Launch Success: Rocket Lab USA (RKLB) shares advanced 2% after completing its 85th launch, successfully deploying two satellites for the European Space Agency's Celeste navigation demonstration mission, underscoring its commitment to supporting global government space programs.
- Origin Materials Revenue Drop: Origin Materials (ORGN) shares plunged 17% after reporting weak Q4 results, with revenue falling to $3.0M from $9.2M a year ago, driven by a planned reduction in its supply chain activation program, leading to a net loss of $194.1M, reflecting significant operational challenges.
See More
GSK's Exdensur Approved in China for Severe Asthma Treatment
- Drug Approval: GSK's Exdensur (depemokimab) has been approved by China's National Medical Products Administration as an add-on maintenance treatment for severe asthma in patients aged 12 and older, marking a significant advancement in the company's respiratory portfolio.
- Clinical Trial Support: The approval is based on data from the SWIFT-1 and SWIFT-2 phase III trials, demonstrating Exdensur's efficacy in improving patient symptoms, providing a robust scientific foundation for GSK's innovations in asthma treatment.
- Market Strategy: GSK's SVP, Global Head of Respiratory, Immunology & Inflammation R&D, Kaivan Khavandi, stated that with Exdensur approved in several major markets, the company aims to transform the treatment paradigm for severe asthma, further solidifying its market leadership.
- Stock Performance: At the last close, GSK shares were trading at 2,049.00 pence, and the market's reaction to the drug approval could potentially drive the stock price higher, boosting investor confidence.
See More
Vaccines Become a Backburner Issue for Trump Administration Ahead of Midterms
- Shift in Vaccine Policy: Robert Malone, a former member of the CDC's Advisory Committee on Immunization Practices, stated that the Trump administration has relegated vaccines to a secondary issue, viewing it as a 'losing issue,' which indicates a strategic pivot ahead of the midterm elections.
- Political Decision Impact: Malone highlighted that the administration has concluded that the MAHA coalition and the constituents they represent are inconsequential for the midterms, suggesting that this assessment could significantly influence the future direction of vaccine policies as voter priorities shift.
- Vaccine Injury Compensation Request: An anti-vaccine group has petitioned HHS Secretary Robert F. Kennedy Jr. to expand the list of alleged vaccine-related injuries under the Vaccine Injury Compensation Program, a move that may spark broader societal discussions and policy reconsiderations regarding vaccine safety.
- CDC Leadership Nomination Delay: The White House has missed the deadline for nominating a new CDC director, reflecting ongoing uncertainty in vaccine policy and public health leadership, which could impact future public health decisions and vaccine promotion efforts.
See More
